Novaliq GmbH, has formed and funded Betaliq Inc., a new company located in Tampa, Florida. Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people currently affected by the condition. The US glaucoma market of more than 3.7 million diagnosed patients is expected to expand further due to an aging population. Ophthalmic [sz]-blockers are a sizeable and growing therapeutic option in this market.1
Betaliq Inc. is a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the General Corporation Law).
Betaliq's pipeline consists of two preservative free glaucoma drug candidates based on new in class and best in class [sz]-blocker molecules using Novaliq's waterfree EyeSol technology. EyeSol is the worldwide first and only water- free technology for ophthalmology products. Two EyeSol based ophthalmic products are currently approved in Europe and two active INDs are in late-stage in the United States.
Betaliq is backed by an experienced management team lead by Barry Butler, a successful entrepreneur with 30 years of pharmaceutical experience serving as Chief Executive Officer of the company, and a highly experienced management team. Recently the company has successfully closed a Series A financing to fund the company and to conduct phase 2 trials in the United States.
The EyeSol technology offers important advantages over traditional eye drop technology, including a drop size approxately 1/4 of the size of water-based drops. This smaller drop size has the potential to result in less systemic absorption. Other advantages of EyeSol include longer residence time on the eye, better penetration, and no need for toxic preservatives.
Betaliq, Inc. is a collaboration between Novaliq GmbH, and BLP Management Group, LLC. Betaliq was formed to develop ophthalmic beta blockers using Novaliq's patented EyeSol[R] non-water formulation technology. EyeSol is the first and only water-free eye drop technology for ophthalmology products. The EyeSol technology offers important advantages over traditional eye drops, including a drop size approximately 1/4 of the size of water-based drops. This smaller drop size has the potential to result in less systemic absorption. Other advantages of EyeSol[R] include longer residence time on the eye, better penetration, and no need for toxic...